Samsung Biologics has entered into a contract for the contract manufacturing of pharmaceuticals worth approximately 93.5 billion won ($83.5 million) with a global pharmaceutical company.
On October 2, Samsung Biologics announced that it had signed a contract with a European pharmaceutical company for a total of 93,478,620,000 won. This amount represents 2.05% of the company's consolidated revenue reported at the end of last year.
The contract period runs from today until December 31, 2031.
The identity of the contracting party will be disclosed at the end of the contract due to confidentiality reasons. The company noted that this date may change.
Meanwhile, the Samsung Biologics Labor Union announced 'Guideline No. 2' for all members today. The union plans to initiate a second general strike for three weeks starting October 26.
On October 1, the two sides held a third post-adjustment meeting at the Incheon Regional Labor Relations Commission but failed to reach a final agreement. They could not even schedule a fourth post-adjustment meeting, concluding that it would be difficult to narrow the differences even with further adjustments.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.